Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Venetoclax Therapy After Complete Remission in Fit AML Patients
ChiCTR2500111062Phase 3Not yet recruiting
- Sponsor
- Sohag University
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in acute myeloid leukemia (AML) comparing venetoclax group with placebo / best supportive care group (2 arms). Primary endpoint: disease free survival. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2500111062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111062.